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Abstract
Summary There are differences in the risk profile of
patients prescribed alendronate, risedronate, or ibandronate.
Observed reductions in fracture incidence over time suggest
that the effectiveness of each bisphosphonate in clinical
practice has been consistent with their efficacies demon-
strated in randomized controlled trials.
Introduction Observational studies of bisphosphonate
effectiveness for fracture prevention are subject to bias
from unknown characteristics of baseline fracture risk at
the start of therapy. The fracture incidence during the
short period after starting a bisphosphonate and before
any expected clinical benefit likely reflects baseline
fracture risk. Bisphosphonate effectiveness may then be
estimated by measuring the change in fracture incidence
over time on therapy.
Methods Administrative billing data were used to follow
three cohorts of women aged 65 and older (total
n=210,144) after starting therapy either on alendronate,
risedronate, or ibandronate in the USA between market
introduction and 2006. Within each cohort, the baseline
incidence of clinical fractures at the hip, vertebral, and
nonvertebral sites was defined by the initial 3-month period
after starting therapy. Relative to these baselines, we then
compared the fracture incidence during the subsequent
12 months on therapy.
Results At the start of therapy, the ibandronate cohort was
younger and had fewer prior fractures than either the
risedronate or alendronate cohorts. Accordingly, the base-
line incidence of hip fractures was higher in the risedronate
cohort (0.90 per 100 person-years) and in the alendronate
cohort (0.77) than in the ibandronate cohort (0.64). Relative
to the baseline incidence, fracture incidence was signifi-
cantly lower in the subsequent 12 months in both cohorts of
alendronate (18% lower at hip, 28% at nonvertebral sites,
and 57% at vertebral sites) and risedronate (27% lower at
hip, 21% at nonvertebral sites, and 54% at vertebral sites).
In the ibandronate cohort, the fracture incidence was lower
(31%) only at vertebral sites.
Conclusions Differences in the baseline fracture incidence
among the cohorts may reflect differences in the risk profile
of patients prescribed each bisphosphonate. The reductions
observed in fracture incidence over time within each cohort
suggest that the effectiveness of each bisphosphonate in
clinical practice has been consistent with their efficacies
demonstrated in randomized controlled trials.
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The demonstrated efficacy of a therapy in a randomized
clinical trial may not predict its actual effectiveness in
clinical practice because of differences in characteristics of
patients and level of medical care [1]. As a therapy for
osteoporosis, the oral bisphosphonates have been widely
utilized in recent years. These bisphosphonates include
once-a-week alendronate (marketed in the USA since
2000), once-a-week risedronate (since 2002), and once-a-
month ibandronate (since 2005). Since health data on large
numbers of bisphosphonate patients in clinical practice
have now been collected (through administrative billing
data, medical records, and registries), many recent obser-
vational studies have examined the effectiveness of oral
bisphosphonates for reducing clinical fractures. The designs
of these observational studies have included comparisons
between patient populations with or without a fracture
[2, 3], with or without bisphosphonate use [4, 5], compliant
or not compliant with bisphosphonate use [6–19], or between
patient populations on different bisphosphonate molecules
[20–23]. A key limitation in interpreting any of these
comparisons is uncertainty if known or unknown differences
in baseline fracture risk between patient populations could
account for some or all of the reported results.
An approach to directly measure the baseline risk of
an outcome within patient populations that has been
used in effectiveness studies of other therapies may be
applicable to the study of bisphosphonates. In a
comparison of patients receiving a bare or drug-eluting
stent, the mortality 2 days after procedure was used to
assess risk of the mortality outcome independent of
possible drug effect [24]. In a comparison of patients
receiving influenza vaccine or not, the mortality after
vaccination but before flu season was used to assess risk
of mortality outcome independent of possible vaccination
effect [25]. Likewise, following initiation of bisphospho-
nate therapy, the realization of fracture reduction is likely
not immediate. Bone mineral density, a surrogate marker
of therapeutic effect, begins to change after start of
therapy though does not reach its maximum level of
change until at least 1 year on therapy [26]. As changes in
bone density and quality take time, correspondingly,
fracture reductions have not been noted earlier than
6 months after start of therapy within post hoc, pooled
analysis of clinical trials [27, 28].
Hence, for an observational study of bisphosphonates,
the fracture incidence during the short period after starting a
therapy and before any expected clinical benefit likely
reflects baseline fracture risk. We propose that bisphosph-
onate effectiveness may then be estimated by measuring the
change in fracture incidence over time on therapy. For this
study, administrative billing data were used to follow three
cohorts of women aged 65 and older after starting therapy
either on alendronate, risedronate, or ibandronate. Within
each cohort, the baseline incidence of clinical fractures at
the hip, vertebral, and nonvertebral sites was defined by the
initial 3-month period after starting therapy. Relative to
these baselines, we then compared the fracture incidence
during the subsequent 12 months on therapy.
Materials and methods
Data source
Computerized records of administrative billing provide a
convenient data source for studying drug use and outcomes
in large populations. Records include patient-level data of:
(1) inpatient and outpatient services specified by diagnoses
codes of the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM); (2) retail and
mail-order pharmacy dispensations specified by national
drug codes; and (3) demographic information including sex,
age, and eligibility dates of health plan coverage. The data
for this study, inclusive of January 2000–December 2007,
originated from two mutually exclusive sources: Ingenix
Lab/Rx (Eden Prairie, MN, USA) and Medstat MarketScan
(Ann Arbor, MI, USA). During that period, the average
number of eligible enrollees was 14 million in Medstat,
representing multiple health plans, and 10 million in
Ingenix, representing a single health plan. Geographically,
one half of this population was located in Michigan,
California, Florida, Ohio, Georgia, or Texas and one half
in the other 44 states.
Study population
The study population consisted of three cohorts—one
prescribed alendronate, one prescribed risedronate, and
one prescribed ibandronate. Subjects entered a cohort on
the date of their initial filled prescription for alendronate
70 mg/week, risedronate 35 mg/week, or ibandronate
150 mg/month during the time period of market introduc-
tion through December 2006. Market introduction was
November 2000 for alendronate cohort, May 2002 for
risedronate cohort, and April 2005 for ibandronate cohort.
The initial bisphosphonate prescription was defined by a
subject having at least 6 months of prior coverage in the
data source without any other bisphosphonate use (e.g.,
another bisphosphonate type or dose). After 6 months
without any bisphosphonate use, a subject was allowed to
enter a new cohort (i.e., a subject could be in more than one
cohort—1% of alendronate cohort, 4% of risedronate
cohort, and 20% of ibandronate cohort was preceded by
inclusion in another cohort).
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aged 65 and over to provide a study population similar in
age to that of the randomized controlled trials and for
which clinical fractures are likely to be related to
osteoporosis [29]; (2) have at least 3 months of coverage
in data source after cohort entry to provide for minimum
follow-up; and (3) have no diagnosis of malignant
neoplasm (ICD-9-CM codes 140–208) or Paget’sd i s e a s e
(731.0) within 6 months prior- and 3 months post-cohort
entry to maximize the probability that subjects were being
treated for either post-menopausal osteoporosis or
glucocorticoid-induced osteoporosis.
Risk factors for fracture
Available risk factors in the data source included age,
history of prior fracture, glucocorticoid use, and diag-
nosis of rheumatoid arthritis. Age was calculated at the
year of cohort entry. History of prior fracture was
defined by any clinical fracture diagnosis at the hip,
wrist, humerus, clavicle, pelvis, leg, or vertebrae in the
6 months prior to cohort entry. Glucocorticoid use was
defined by receiving 450 mg prednisone-equivalent pills
within ±90 days of cohort entry—an approximation of
the American College of Rheumatology guideline of
5m gp r e d n i s o n ef o ra tl e a s t9 0d a y s[ 30]. A diagnosis
of rheumatoid arthritis was based on any inpatient or
outpatient diagnosis (ICD-9-CM code 714.0) within
6 months prior- and 3 months post-cohort entry. Risk
factors not available in the data source included bone
mineral density, body mass index, smoking, alcohol
consumption, and family history of fracture.
Fracture outcomes
After subjects entered a cohort, each was followed to
identify three outcomes: a new hip fracture, a new
nonvertebral fracture, or a new clinical vertebral fracture.
During the follow-up, subjects were allowed to have each
outcome once. Hip fractures were defined by an inpatient
diagnosis at the hip (ICD-9-CM code 820, 733.14).
Nonvertebral fractures were inclusive of inpatient diag-
A) Identification
January  2000 December 2007
November 2000 December 2006
May 2002
April 2005
Period of data source
Period of initial bisphosphonate for inclusion in cohort of:
alendronate
risedronate
ibandronate
B)  Follow-up
Cohort
entry
End of
3 months
End of
6 months
End of
9 months
End of
12 months
End of
15 months
ibandronate
subjects in data source
and high compliance
14,288 14,288
10,426
13,444
7,756
12,553
5,447
12,975
6,595
risedronate
subjects in data source
and high compliance
78,860 78,860
55,842
73,629
39,228
64,448
28,132
68,694
34,232
alendronate
subjects in data source 
and high compliance
116,996 116,996
84,534
110,333
61,594
98,583
45,802
104,098
54,681
(84%) A
(46%) B
(82%)
(44%)
(88%)
(43%)
Initial period
of therapy
Subsequent period
of therapy
A of subjects entering cohort, percentage remaining in data source after 12 months 
B of subjects remaining in data source, percentage maintaining high compliance to therapy (medical 
possession ratio    80%)
Fig. 1 Time period for cohort
identification and follow-up for
measure of fracture incidence
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the wrist (813, 733.12), humerus (812, 733.11), clavicle
(810), pelvis (808), and leg (821, 823, 733.15, 733.16).
Clinical vertebral fractures were defined by either inpa-
tient or outpatient diagnosis at vertebral sites (805.2,
805.4, 805.8, 733.13). New fractures were defined as a
fracture at each body site for which there was no fracture
at that same site in the 6 months before cohort entry. To
increase the probability of only including osteoporotic-
related fractures, we excluded likely traumatic fractures
by eliminating diagnoses of an open fracture or of a
documented cause of injury other than an accidental fall
(ecode of E880–E888). These exclusions removed less
than 10% of fracture outcomes.
Follow-up
All subjects contributed 3 months of follow-up after cohort
entry, during which the baseline fracture incidence was
calculated. The denominator was the sum of observation
time for all subjects within a cohort during the 3 months.
For example, within the alendronate cohort, the 116,996
subjects contributed 91 days of follow-up each for
10.6 million days/364 days per year or 29,249 person-years
of observation. The numerator was number of subjects with
a new fracture during the 3 months.
After 3 months of follow-up, subsequent observation
was available for subjects through December 2007
unless their individual coverage ceased in the data
source (Fig. 1a). The fracture incidence was calculated
for the subsequent 1 year on therapy. We limited our
observation to the subsequent 1 year of therapy because of
concerns that a subject's fracture risk may change over a
period of multiple years independent of any therapeutic
effect. Two examples of changing fracture risk over time
include: the risk of hip fracture increasing with each year
of age [31] and the risk of fractures increasing substan-
tially within the year after a fracture but then decreasing
thereafter [32]. All subjects who had received a sufficient
quantity of pills (of the same bisphosphonate type
initiated at cohort entry) to provide for a medical
possession ratio ≥80% at the end of 3 months were
followed into the subsequent 3-month period (Fig. 1b).
The level utilized for the medical possession ratio has
been frequently suggested to provide a high level of
therapy effectiveness for bisphosphonates [6–19]. Subjects
Table 1 Baseline characteristics of study population
Alendronate Risedronate Ibandronate
70 mg 35 mg 150 mg
Number of women in cohort 116,996 78,860 14,288
Year of cohort entry, % cohort
2000–2004 78% 73% 0%
2005–2006 22% 27% 100%
Age at cohort entry, mean 75 76 75
Age 75 and over, % cohort 51% 53% 47%
Clinical fracture in 6 months before cohort entry
a 9% 9% 7%
Clinical fracture in 4 years before cohort entry
b 19% 18% 17%
Glucocorticoid use at cohort entry 5% 6% 6%
Rheumatoid arthritis diagnosis at cohort entry 2% 3% 3%
Hormone replacement therapy at cohort entry 14% 12% 9%
Prior bisphosphonate use, % cohort
c
6 months before cohort entry 0% 0% 0%
1 year 4% 5% 18%
2 years 6% 10% 30%
3 years 7% 12% 36%
4 years 7% 13% 40%
aFracture diagnosis at the hip, clavicle, wrist, humerus, leg, pelvis, or vertebral sites
bFracture diagnosis at any time in the 4 years before cohort entry among those with 4 years of available administrative billing data before cohort
entry (17,128 subjects in alendronate cohort had 4 years of such data, 15,054 in risedronate cohort, 7,884 in ibandronate cohort)
cUse of any bisphosphonate (e.g., daily formulations or other bisphosphonate) before cohort entry regardless of duration of administrative billing
data before entry. Note: among those with 4 years of available data before entry, the percent of cohort in the preceding 4 years with
bisphosphonate use was 9%, 19%, and 47% for alendronate, risedronate, and ibandronate cohorts, respectively
1024 Osteoporos Int (2010) 21:1021–1029were followed until the end of this 3-month period or the
end of their coverage in data source. The same process
was applied at the end of 6, 9, and 12 months after cohort
entry. For the calculation of incidence, the denominator
was the sum of observation during follow-up preceded by
a medical possession ratio of at least 80%. For example,
within the alendronate cohort:
84,534 subjects had an average of 89 days of follow-
up between 3 and 6 months of therapy, 61,594 subjects
had an average of 89 days of follow-up between 6 and
9 months of therapy, 54,681 subjects had an average of
89 days of follow-up between 9 and 12 months of
therapy, and 45,802 subjects had an average of 89 days
of follow-up between 12 and 15 months of therapy—for
a sum of 60,108 person-years of observation. The
numerator included number of subjects with a new
fracture, preceded by medical possession ratio of 80%,
akin to previous study [7].
Statistical analysis
A simple ratio was used to compare the incidence of
fractures between the period of 3 months after starting
therapy and the subsequent 1-year period on therapy.
Poisson regression was used to compute the 95% confi-
dence intervals around the ratio. An independent review
and replication of statistical analyses was completed by
Esteban Walker, Ph.D., of the Department of Quantitative
Health Sciences at the Cleveland Clinic.
Results
Cohort characteristics
The study population included women who entered into a
cohort on the date of their initial filled prescription for
alendronate 70 mg (n=116,996) or risedronate 35 mg
(n=78,860) or ibandronate 150 mg (n=14,288) (Fig. 1a).
The data source provided a record of health care utilization
for at least 1 year after initial bisphosphonate prescription
for more than 80% of each cohort (Fig. 1b). Of those
subjects in the data source for at least 1 year, between 43%
and 46% of the cohorts were highly compliant to therapy
(i.e., maintained a medical possession ratio to initiated
therapy of at least 80%).
At cohort entry, the ibandronate cohort was the youngest
and had the smallest percentage with a recent fracture
history among the three cohorts (Table 1). Since a subject
was allowed to enter a cohort after 6 months without any
bisphosphonate use, some subjects had some previous use
of bisphosphonates. Prior use of bisphosphonates in the
4 years prior to cohort entry ranged from 7% of alendronate
cohort to 40% of ibandronate cohort.
Table 2 Incidence of hip fractures in the 3 months after starting therapy by baseline characteristic
Alendronate (n=116,996)
(person-years=29,249)
Risedronate (n=78,860)
(person-years=19,715)
Ibandronate (n=14,288)
(person-years=3,572)
%
cohort
Number of
fractures
Rate/100
p-y
%
cohort
Number of
fractures
Rate/100
p-y
%
cohort
Number
fracture
Rate/100
p-y
Complete cohort 100 225 0.77 100 177 0.90 100 23 0.64
Cohort entry 2000–2004 78 166 0.78 73 113 0.86 0
Cohort entry 2005–2006 22 59 0.74 27 64 0.97 100 23 0.64
Age 65–74 years 49 38 0.26 47 33 0.35 53 5 0.26
Age 75 and over 51 187 1.26 53 144 1.38 47 18 1.07
Glucocorticoid use 5 20 1.26 6 18 1.55 6 1 –
No glucocorticoid use 95 205 0.74 94 159 0.86 94 22 0.65
Hormone therapy use 14 23 0.55 12 9 0.37 9 1 –
No hormone use 86 202 0.81 88 168 0.97 91 22 0.68
Prior clinical fracture
a 9 49 1.86 9 32 1.85 7 1 –
No fracture 91 176 0.66 91 145 0.81 93 22 0.66
Prior bisphosphonate use
b 7 19 0.90 13 28 1.09 40 10 0.71
No prior use 93 206 0.76 87 149 0.87 60 13 0.60
p-y person-years. The calculation of rate is based on the number of fractures divided person-years of observation during first 3 months after
starting therapy. No rates reported for three or less fractures
aIn the 6 months before cohort entry, any clinical fracture diagnosis at the hip, clavicle, wrist, humerus, leg, pelvis, or vertebral sites
bIn the 4 years before cohort entry, use of any bisphosphonate regardless of duration of administrative billing data before cohort entry.
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During the 3 months after starting therapy in all three
cohorts, the incidence of hip fractures was higher among
those of greater age, prior fracture history, and glucocorti-
coid use, and lower among those with use of hormone
replacement therapy (Table 2). During these 3 months,
patients receiving risedronate had an incidence of hip
fractures that was 141% of the incidence among those
receiving ibandronate and 117% of the incidence among
those receiving alendronate. After statistically adjusting (by
direct standardization to risedronate cohort) for age,
fracture history, and prior bisphosphonate use, patients
receiving risedronate had an incidence of hip fractures that
was 132% of the incidence among those receiving
ibandronate and 114% of the incidence among those
receiving alendronate.
Change in fracture incidence over time
After the initial 3-month period, the incidence of fractures
was observed in the subsequent 1 year while on therapy.
Relative to the baseline incidence of the initial 3-month
period, the incidence of clinical fractures at the hip,
vertebral, and nonvertebral sites was significantly lower in
the subsequent 12 months in both cohorts of alendronate
and risedronate (Table 3). The incidence of vertebral
fractures in the subsequent 1 year was lower in the
ibandronate cohort.
We examinedwhether differentlevelsoffractureriskatthe
start of therapy modified the longitudinal change in fracture
incidence—by using stratification to limit the analyses to
subgroups of similar baseline characteristics of fracture risk.
The strata were based upon prior clinical fracture (yes or no),
prior bisphosphonate use (yes or no), age (one quantile above
or below population median of 75 years), and date of study
entry (period before or after all three therapies were on the
market). For every subgroup, its 95% confidence interval
included the point estimate of overall analyses (Fig. 2).
Discussion
In this observational study of cohorts containing patients
starting alendronate, risedronate, or ibandronate, there were
apparent differences among the cohorts in age and prior
fracture history, in prior use of bisphosphonates, and in the
fracture incidence during the short period after starting
therapy and before any expected clinical benefit. These
differences in the risk profile of patients prescribed each
bisphosphonate are significant for the consideration of bias
in interpretation of results of any observational study of
bisphosphonates.
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inclusion criterion for new use of bisphosphonate was
defined by a subject having at least 6 months of no other
bisphosphonate use. In order to further evaluate this
criterion, we were able to examine up to four prior years
for a subset of the population. As evident by the large
number of ibandronate patients in this study with prior
bisphosphonate use, the six month criterion was not always
adequate to truly define new users of bisphosphonates.
Indeed, the median gap between stopping and restarting
bisphosphonate therapy has been reported to be 16 months
[33]. Since bisphosphonates have residual treatment effects,
for example, alendronate has effects for up to 5 years after
stopping treatment [34], it may not be readily possible to
disentangle the fracture outcome with the current
bisphosphonate exposure from past bisphosphonate
exposure [35].
The study approach to account for differences in patient
profiles is often techniques of regression modeling, pro-
pensity score modeling, or instrument variable analysis
[36]. However, statistical techniques cannot exclude the
possibility of bias arising from the nonrandom allocation of
subjects [37]. In the current study, given the differences
between cohorts in patient profiles including prior use of
bisphosphonates, we proposed a study design that estimated
bisphosphonate effectives by measuring the change in
fracture incidence over time within a cohort. In such an
approach, the cohort population receiving the same therapy
is its own control, thus limiting the potential bias associated
with a comparison of outcomes between cohorts.
In this study, two observations suggested that change in
fracture incidence over time within a cohort may indeed be
utilized to measure bisphosphonate effectiveness. The first
observation supporting the study design was that the
baseline fracture incidence during the initial 3 months after
starting therapy accurately reflected the underlying risk of
cohort. During this baseline period, the incidence of hip
fractures corresponded with well-accepted risk factors for
fracture, including age, prior fracture history, and gluco-
corticoid use [38]. These relationships between risk factors
and fracture incidence were consistently observed across all
three cohorts (Table 2). The second observation supporting
the study design was the consistency in results between this
observational study and the prospectively planned analyses
of respective phase III randomized controlled trials [39–45].
As summarized in a government-funded systematic review
of bisphosphonates [46], alendronate, risedronate, and
ibandronate have all been shown to reduce vertebral
Baseline Characteristic
Alendronate
(n = 116,996)
Risedronate
(n = 78,860)
Ibandronate
(n = 14,288)
Complete cohort
Study entry 2000 - 04
Study entry 2005 - 06 
Age 65 - 74 years
Age 75 and over
Prior clinical fracture
No fracture
Prior bisphosphonate use
No prior use
0.4 0.5 0.7 1 1.5 2 2.5
Fracture incidence
lower during follow-up
than during baseline
Fracture incidence
higher during follow-up
than during baseline
0.40.5 0.7 1 1.5 2 2.5 0.40.5 0.7 1 1.5 2 2.5
*1
*2
*
1  Not applicable 
*
2  Rate ratios not reported when    3 hip fractures in either baseline or follow-up period
Fig. 2 Ratio and 95% confidence interval of hip fracture incidence for subsequent 1 year on therapy (follow-up) versus 3-month period after
starting therapy (baseline)—subgroup analyses
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shown to reduce nonvertebral fractures, including hip
fractures. Of note, the results of subgroup [45] or post
hoc [47] analyses of randomized controlled trial data have
suggested a reduction of nonvertebral fractures among
subjects using ibandronate. To date, no data from random-
ized controlled trials appear available in the literature
concerning hip fractures and ibandronate.
There are several limitations in interpretation of change
in fracture incidence as a measure of bisphosphonate
effectiveness. One limitation arises from the differences in
risk profile of patients between cohorts. It is conceivable
that the lack of an observable effectiveness on non-
vertebral fractures for ibandronate could relate to the
lower risk profile of those patients. In a study of another
bisphosphonate, clodronate, the magnitude of fracture
reduction was greatest among those at highest probability
of fracture [48]. Another limitation in interpretation of
results comes from the relatively small sample size of
ibandronate cohort relative to the other cohorts. Hence, the
95% confidence interval (0.71–1.88) around the estimate
of longitudinal change in hip fracture incidence was the
widest in the ibandronate cohort. A third limitation in
interpretation of results is the data source does not indicate
the reason starting therapy (e.g., post-menopausal osteo-
porosis or glucocorticoid-induced osteoporosis), hence
these results may not generalize to defined populations.
An additional limitation in interpretation may arise from
misclassification of outcomes. In a prior study, the
proportion of fracture claims confirmed by chart review
to be a fracture was highest for the hip relative to other
fracture sites [49]. Since the effect of misclassification of
outcomes is likely no different between cohorts (i.e.,
misclassification does not depend on cohort), the study
results for the measure of nonvertebral sites and for
vertebral sites are likely more attenuated by misclassifi-
cation than results at the hip.
In conclusion, for this large observational study of more
than 200,000 bisphosphonate patients, the apparent differ-
ences in the baseline incidence of hip fractures among the
alendronate, risedronate, and ibandronate cohorts likely
reflect differences in the risk profile of patients prescribed
each bisphosphonate. Statistical adjustments could not
account for these differences and therefore the design of
epidemiological studies should be given careful consider-
ation to account for these differences. Relative to the
baseline fracture incidence, the longitudinal analyses
indicated that alendronate and risedronate decreased non-
vertebral and hip fractures over time, whereas ibandronate
did not. All three bisphosphonates decreased vertebral
fractures. The reductions observed in fracture incidence
over time within each cohort suggest that the effectiveness
of each bisphosphonate in clinical practice has been
consistent with their efficacies demonstrated in randomized
controlled trials.
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